Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | MicrobiomeTrials← Back to trialsNCT03150329
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2017-07-18Est. Completion: 2023-06-23
Enrollment target: 52 participants Locations- City of Hope Medical Center, Duarte, California, United States
Other microbiome trials you might be interested in
Diffuse Large B-cell-lymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3BPMBLHGBL With MYC and BCL2 and/or BCL6 RearrangementsHGBL, Nos
This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refract…
Tianjin, ChinaEst. completion Apr 28, 2029
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Grade 3b Follicular Lymphoma
Recurrent High-Grade B-Cell Lymphoma
Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Grade 3b Follicular Lymphoma
Refractory High-Grade B-Cell Lymphoma
Refractory Indolent B-Cell Non-Hodgkin Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
This phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed …
Seattle, United StatesCompleted Oct 4, 2030
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Refractory Large B-cell Lymphoma (LBCL)Refractory T-cell/Histiocyte-rich Large B-cell LymphomaRefractory Transformed Follicular LymphomaRefractory High-Grade B-Cell LymphomaRefractory Follicular Lymphoma Grade 3B
The goal of this Phase 2, open-label, multicenter clinical trial is to assess the efficacy and safety of accelerated ram…
Créteil, FranceEst. completion Jul 2028